IL2 and pancreatic neoplasm: To test the effectiveness of different immunocytokines in pancreatic tumor models, C57BL/6J mice (RRID:IMSR_JAX:000664) were orthotopically injected with KPC06 and randomly assigned to receive once a week for 2 weeks: vehicle, as CTR, L19-IL2 high dose (100 μg/mouse), L19mIL12 (12 μg/mouse), mIL2-F8-mTNF(mut) (40 μg/mouse), L19mTNF (4 μg/mouse), standard chemotherapy with gemcitabine 10 mg/kg + abraxane 3 mg/kg (Gem/Abx) (Supplementary Fig. 3).